Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Singh Discusses the Shift Toward Stereotactic Radiation Therapy in Lung Cancer

April 23rd 2024

Raj Singh, MD, discusses the use of stereotactic body radiation therapy and stereotactic radiosurgery in the treatment of patients with lung cancer.

Early Data for CRX100 Pave Way for Potential Combinations in Recurrent, Platinum-Resistant Ovarian Cancer

April 22nd 2024

Oliver Dorigo, MD, PhD, discusses the investigation of CRX100 in patients with recurrent, platinum-resistant ovarian cancer.

Tivumecirnon Plus Pembrolizumab Shows Activity in Checkpoint Inhibitor–Exposed Recurrent/Metastatic HNSCC

April 21st 2024

Tivumecirnon plus pembrolizumab elicited responses in recurrent or metastatic head and neck squamous cell carcinoma after checkpoint inhibitor exposure.

Pembrolizumab/Lenvatinib Extends Survival in Advanced/Recurrent Endometrial Cancer Subgroups

April 15th 2024

Christian Marth, MD, PhD, discusses outcomes for key subgroups treated with first-line pembrolizumab and lenvatinib in advanced or recurrent endometrial cancer.

Iglesia Spotlights the Current Complexities of Treatment Sequencing in Advanced HCC

April 5th 2024

Michael Iglesia, MD, PhD, discusses the effects of the phase 3 CELESTIAL trial on treatment sequencing strategies in advanced hepatocellular carcinoma.

Patient Selection Key for Focal Therapy in Intermediate Prostate Cancer

April 5th 2024

Ruben Olivares, MD, discusses the integration of focal therapy in the treatment of patients with intermediate prostate cancer.

Zamarin Shares Updates and Ongoing Research Endeavors in Gynecologic Oncology

March 29th 2024

Dmitriy Zamarin, MD, PhD, highlights key changes and ongoing research across the endometrial, ovarian, and cervical cancer realms.

Efstathiou on the Status of Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer

March 27th 2024

Jason Efstathiou, MD, discusses the status of bladder preservation therapy for muscle-invasive bladder cancer.

Shifting Therapies to Earlier Settings Could Bolster Treatment Options in mHSPC and Oligometastatic Prostate Cancer

March 26th 2024

Neeraj Agarwal, MD, FASCO, discusses unmet needs across the prostate cancer spectrum and ongoing trials investigating agents in earlier settings.

Looking Beyond PSA Is Key to Understanding Nuances of Prostate Cancer Treatment

March 25th 2024

Robert Dreicer, MD, discusses the complex landscape of prostate cancer treatment, highlighting key points from his presentation at the 2024 NY GU.

Taplin Tackles Equitable Treatment in Prostate Cancer

March 24th 2024

Mary-Ellen Taplin, MD, discusses ways to mitigate health care disparities in the treatment of patients with prostate cancer.

Advancing Cellular Therapies in Solid Tumors: Current Challenges and Future Directions

March 21st 2024

Jay Spiegel, MD, discusses advancing cellular therapies and challenges in gynecologic cancer treatment.

2024 ACRO Summit Underscores the Importance of Continued Education in Radiation

March 20th 2024

Steven E. Finkelstein, MD, DABR, FACRO, discusses the importance of disseminating treatment advancements and ongoing research in radiation oncology.

Q-TWiST Analysis Demonstrates Benefit of Fruquintinib Plus BSC in Pretreated mCRC

March 12th 2024

Sebastien Stintzing, MD, discusses a Q-TWiST analysis for fruquintinib vs placebo in pretreated metastatic colorectal cancer.

Osimertinib Plus Chemo Adds Combination Strategy to Advanced EGFR+ NSCLC Armamentarium

February 28th 2024

Pasi A. Jänne, MD, PhD discusses the FDA approval of osimertinib plus chemotherapy for patients with EGFR-positive non–small cell lung cancer.

Pembrolizumab Plus Chemotherapy Elicits Continued Survival Benefit in Advanced Esophageal Cancer

February 26th 2024

Manish A. Shah, MD, discusses 5-year outcomes from phase 3 KEYNOTE-590 study of first-line pembrolizumab plus chemotherapy for advanced esophageal cancer.